HiLung Inc. is proud to participate as an Innovation Partner at the Investigative & Preclinical Toxicology Summit 2026 in Boston, USA — a premier international conference dedicated to predictive toxicology and New Approach Methodologies (NAMs).
At the summit, HiLung will showcase its proprietary human iPSC-derived respiratory platforms, including respiratory organoids, ALI systems, tissue-resident alveolar macrophage models, and lumen-accessible alveolar organoid technologies (HiFOAms^TM, HiAlv-ALI^TM, HiTrach-ALI^TM, HiTRAM^TM, and PAcinOs^TM).
These next-generation human-relevant platforms are designed to advance pulmonary toxicity assessment, drug-induced lung injury (DILI/DIILD) evaluation, and viral respiratory toxicity research with greater translational relevance to human biology.